title: Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis.
abstract: This study reports the anti-anaerobic properties of ranbezolid, a new investigational oxazolidinone. A time-kill kinetics study against anaerobes showed that ranbezolid was superior to linezolid and killed the anaerobic pathogens at 4-8h, except for Bacteroides fragilis where killing was observed at 24h. In addition, the time-kill kinetics study showed a concentration-dependent bactericidal potential of ranbezolid against anaerobes. Ranbezolid showed 5.39log(10) reduction and linezolid showed 1.15log(10) reduction in murine disk implant infection with B. fragilis ATCC 25285. Ranbezolid was very potent and showed fast protein synthesis inhibition against B. fragilis, a Gram-negative anaerobe. In addition, non-specific cell wall synthesis inhibition was also observed with ranbezolid. The potent and fast protein synthesis inhibition along with an additional mode of action of cell wall synthesis inhibition could be responsible for the cidal effect of ranbezolid against Gram-negative anaerobes.
authors.affiliation: Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, R&D III, Sector 18, Gurgaon, India.
authors.forename: Tarun
authors.initials: T
authors.lastname: Mathur
authors.forename: Vandana
authors.initials: V
authors.lastname: Kalia
authors.forename: Tarani Kanta
authors.initials: TK
authors.lastname: Barman
authors.forename: Smita
authors.initials: S
authors.lastname: Singhal
authors.forename: Seema
authors.initials: S
authors.lastname: Khan
authors.forename: Dilip J
authors.initials: DJ
authors.lastname: Upadhyay
authors.forename: Ashok
authors.initials: A
authors.lastname: Rattan
authors.forename: V Samuel
authors.initials: VS
authors.lastname: Raj
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy; D001441:Bacteroides fragilis / Q000187:drug effects*; D002473:Cell Wall / Q000187:drug effects; D005547:Foreign Bodies / Q000150:complications / Q000382:microbiology; D005663:Furans / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D010080:Oxazoles / Q000494:pharmacology* / Q000627:therapeutic use; D014176:Protein Biosynthesis / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D005663:Furans; D010080:Oxazoles; C476340:ranbezolid